Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29979972 | 1.00 | CHRM2 (0.49) | CHRM2HTR1AADRA2ACYP2D6CHRM1 | |
| SCHEMBL27283741 | 0.90 | KMT2A (0.51) | CHRM2HTR1AADRA2ACYP2D6CHRM1 | |
| SCHEMBL27258963 | 0.88 | SRD5A1 (0.48) | CHRM2HTR1AADRA2ACYP2D6CHRM1 | |
| SCHEMBL28086941 | 0.87 | DPP4 (0.42) | KCNH2MGLLMEN1KMT2A | |
| SCHEMBL27393302 | 0.86 | BLM (0.51) | CHRM2HTR1AADRA2ACYP2D6CHRM1 | |
| SCHEMBL9926016 | 0.84 | SLC6A2 (0.64) | CHRM2HTR1AADRA2ACYP2D6CHRM1 | |
| SCHEMBL18428984 | 0.84 | GPR119 (0.56) | MAPK1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL18469978 | 0.81 | CHRM1 (0.73) | CHRM2HTR1AADRA2ACYP2D6CHRM1 | |
| SCHEMBL9356595 | 0.80 | SLC6A3 (0.58) | CHRM2HTR1AADRA2ACYP2D6CHRM1 | |
| SCHEMBL27177320 | 0.79 | HRH3 (0.43) | CHRM2CYP2D6CHRM1HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3822262-B1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2024-03-27 | — | — | EP | disclosed |
| US-11091456-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-08-17 | — | — | US | disclosed |
| EP-3822262-A1 | MUSCARINIC AGONISTS | Heptares Therapeutics Limited (GB) | 2021-05-19 | — | — | EP | disclosed |
| EP-3331869-B1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2020-12-23 | — | — | EP | disclosed |
| US-20190270718-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-10351545-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-07-16 | — | — | US | disclosed |
| US-10167272-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-01-01 | — | — | US | disclosed |
| EP-3331869-A1 | MUSCARINIC AGONISTS | Heptares Therapeutics Limited (GB) | 2018-06-13 | — | — | EP | disclosed |
| US-20180155315-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-06-07 | — | — | US | disclosed |
| US-20180022726-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-9758506-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-09-12 | — | — | US | disclosed |
| WO-2017021730-A1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-02-09 | — | — | WO | disclosed |
| US-20170037025-A1 | Muscarinic Agonists | NXERA PHARMA UK LIMITED (GB) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091456-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885HTR1A 205/4885ADRA2A 30/4885 |
| US-20180022726-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885HTR1A 205/4885ADRA2A 30/4885 |
| US-20190270718-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885HTR1A 205/4885ADRA2A 30/4885 |
| US-10351545-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885HTR1A 205/4885ADRA2A 30/4885 |
| US-20170037025-A1 | Muscarinic Agonists | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885HTR1A 205/4885ADRA2A 30/4885 |
| US-20180155315-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885HTR1A 205/4885ADRA2A 30/4885 |
| US-10167272-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885HTR1A 205/4885ADRA2A 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.